

P&T Motion History

Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Inhibitors

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
alirocumab evolocumab	After considering the evidence of safety, efficacy and special populations for the treatment of hypercholesterolemia, I move that alirocumab and evolocumab are safe and efficacious for the treatment of their approved indications. PCSK9 Inhibitors can be subject to therapeutic interchange in the Washington preferred drug list. Motion: Wisner 2 nd : Harvey	April 19, 2017	Yes Johnson Chew	Yes Figueroa Johnson	Passed unanimous